Features and clinical significance of nutritional metabolism in patients with primary liver cancer
-
摘要: 营养代谢与肿瘤的治疗密切相关,一方面,以营养代谢通路分子作为治疗靶点,成为生物医学领域研究的新方向;另一方面,肿瘤患者营养状态较差,将导致患者无法进行治疗、副作用较大或预后较差。肝肿瘤代谢具有区别于其他部位肿瘤的营养代谢特点,因此,肝癌患者的营养代谢研究尤为重要。对原发性肝癌患者糖、脂肪、蛋白质和氨基酸代谢的变化及分子机制进行阐述,以期为肝癌患者营养代谢通路的选择、肝癌特异性标志物的确定以及治疗中的营养支持等问题提供解决思路,为肝癌的营养代谢研究提供参考。Abstract: Nutritional metabolism is closely associated with the treatment of tumors and is an important research field in China and foreign countries. On the one hand, the use of nutrient metabolism pathway molecules as therapeutic targets has become a new direction in the field of biomedical research; on the other hand, poor nutritional status in patients with tumors will lead to the fact that the patients cannot be treated or have severe adverse reactions or poor prognosis, and thus it has always been a hot research topic. The liver is a metabolic organ, and the metabolism of liver tumors is different from that of tumors in other parts. Therefore, the research on nutritional metabolism in patients with liver cancer is of particular importance. This article elaborates on the changes in the metabolism of glucose, lipids, proteins, and amino acids and related molecular mechanisms in patients with primary liver cancer, in order to provide thoughts for selecting nutrient metabolism pathways in patients with liver cancer, identifying specific markers for liver cancer, and solving the issue of nutritional support during treatment and provide a reference for the research on nutritional metabolism of liver cancer.
-
Key words:
- carcinoma, hepatocellular /
- carbohydrate metabolism /
- lipid metabolism /
- protein metabolism /
- review
-
[1]HANAHAN D, WEINBERG RA. Hallmarks of cancer:The next generation[J]. Cell, 2011, 144 (5) :646-674. [2]JIAO L, ZHANG HL, LI DD, et al. Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2) [J]. Autophagy, 2018, 14 (4) :671-684. [3]CHEN Z, ZUO X, ZHANG Y, et al. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect[J]. Cell Death Dis, 2018, 9 (5) :549. [4]DEPREZ J, VBRTOMMEN D, ALESSIDR, et al. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades[J]. J Biol Chem, 1997, 272 (28) :17269-17275. [5]SENGUPTA S, PETERSON TR, SABATINI DM. Regulation of the m TOR complex 1 pathway by nutrients, growth factors, and stress[J]. Mol Cell, 2010, 40 (2) :310-322. [6]ZHANG W, PATIL S, CHAUHAN B, et al. FoxO1 regulates multiple metabolic pathways in the liver effects on gluconeogenic, glycolytic, and lipogenic gene expression[J]. J Biol Chem, 2006, 281 (15) :10105-10117. [7]GONG ZG, ZHAO W, ZHANG J. Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis[J]. Oncotarget, 2017, 8 (38) :63890-63900. [8]WANG B, CHEN D, CHEN Y. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry[J]. J Proteome Res, 2012, 11 (2) :1217-1227. [9]HU H, JUVEKAR A, LYSSIOTIS CA, et al. Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton[J]. Cell, 2016, 164 (3) :433-446. [10]WANG MD, WU H, FU GB, et al. Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients[J]. Hepatology, 2016, 63 (4) :1272-1286. [11]GURI Y, COLOMBI M, DAZERT E, et al. m TORC2 promotes tumorigenesis via lipid synthesis[J]. Cancer Cell, 2017, 32 (6) :807-823. [12]HUANG D, LI T, WANG L, et al. Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress[J]. Cell Res, 2016, 26 (10) :1112-1130. [13]YANG Y, LI C, NIE X, et al. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis[J]. J Proteome Res, 2007, 6 (7) :2605-2614. [14]RESSOM HW, XIAO JF, TULI L, et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis[J]. Anal Chim Acta, 2012, 743:90-100. [15]PAVLOVA NN, THOMPSON CB. The emerging hallmarks of cancer metabolism[J]. Cell Metab, 2016, 23 (1) :27-47. [16]BUNGARD CI, MCGIVAN JD. Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter[J]. Biochem J, 2004, 382 (Pt 1) :27-32. [17]SUZUKI S, TANAKA T, POYUROVSKY MV, et al. Phosphateactivated glutaminase (GLS2) , a p53-inducible regulator of glutamine metabolism and reactive oxygen species[J]. Proc Natl Acad Sci U S A, 2010, 107 (16) :7461-7466. [18]HU W, ZHANG C, WU R, et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function[J]. Proc Natl Acad Sci U S A, 2010, 107 (16) :7455-7460. [19]LONG J, LANG ZW, WANG HG, et al. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas[J]. Hepatobiliary Pancreat Dis Int, 2010, 9 (3) :296-305. [20]XU P, OOSTERVEER MH, STEIN S, et al. LRH-1-dependent programming of mitochondrial glutamine processing drives liver cancer[J]. Genes Dev, 2016, 30 (11) :1255-60. [21]DI POTO C, FERRARINI A, ZHAO Y, et al. Metabolomic characterization of hepatocellular carcinoma in patients with liver cirrhosis for biomarker discovery[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26 (5) :675-683. [22]JAIN M, NILSSON R, SHARMA S, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation[J]. Science, 2012, 336 (6084) :1040-1044. [23]ZHANG J, HAO N, LIU W, et al. In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery[J]. Br J Cancer, 2017, 117 (11) :1676-1684.
本文二维码
计量
- 文章访问数: 1177
- HTML全文浏览量: 44
- PDF下载量: 285
- 被引次数: 0